Ann: paxalisib PNOC collaboration, page-10

@moosey

I read you other posts hypothesising about that. I'm not a scientist, just a mug punter, which is why I post mainly from the viewpoint of an investor. Others here seem more across the science.

My posts about Cantrixil yesterday were more around my scepticism that Kazia (and the share price) will realise any value from Cantrixi in the short term. I like the company's stated strategy for Cantrixil of seeking a partner. If that doesn't eventuate I think they should keep it on the shelf. We are still talking in terms of several years to progress it through phase two trials.

I also think the fact that many of us have forgotten the details about Cantrixil is a disappointment. This was the drug that targeted the cancer "stem cells" right?

Once we have a commercial partner for Paxsalisib, that changes everything.